Houstonian Joe Schurman's latest venture PhenomAInon is aimed at tapping into AI and data analytics for for space domain awareness and threat detection. Photo via Getty Images

As artificial intelligence continues to expand its sphere of influence, Spring-based expert Joe Schurman is looking to take this technology to an out-of-this-world space.

With his background includes working with advising defense and aerospace organizations like NASA, Schurman's latest venture PhenomAInon is perfectly aligned with what he’s been working towards since 2019. The company aims to be a multi-tiered subscription service and application that will be the world’s first cloud native data and AI platform for phenomenon-based data analysis that can analyze data from any source for space domain awareness and threat detection, according to Schurman.

The platform aims to provide end-to-end data and AI analysis, publish insights, build community, and provide cloud, data, and software consulting. PhenomAInon deploys data and AI services alongside modern data and AI engineering, per the website, to surface insights to explorers, researchers, organizations, publications, and communities through advanced data and AI analysis. Schurman has worked with the U.S. government's task force for unidentified anomalous phenomenon — any perceived aerial phenomenon that cannot be immediately identified or explained — known as UAPTF. The tool will run sensitive information and then get back custom video analysis. The public version of the tool will give the public the option to view videos and cases, and form their own analysis.

“We are working together with multiple teams both public and private to continue to curate the data sets, clear documents for public review, and provide advanced analytics and AI capabilities never seen before to the public,” Schurman tells InnovationMap. “From a data and analytics perspective, we are applying machine learning and advanced analytics to find correlations and anomalies in the incident reports across multiple data sets.

"Some of these are public, some are private, and some we are clearing for public review," he continues. "The analytics will go far beyond incident reporting and showcase heat maps, correlative incident maps to key private and public sector facilities, and trends analysis never reported — e.g. incident reporting correlated with time, weather, FAA, and drone flight data, etc. We also have a new content analysis platform where users will be able to eventually run their own AI and ML analysis on their own videos.”

Schurman was first able to show this to the world in 2019, when as an adviser for To The Stars Academy of Arts and Science, or TTSA. He also appeared on History Channel’s “Unidentified: Inside America's UFO Investigation” to show the Pentagon’s former Advanced Aerospace Threat Identification Program head and TTSA Director of Special Programs Luis Elizondo how the AI platform could be helpful in tracking data related to Unidentified Aerial Phenomena.

Now, PhenomAInon's app is a work-in-progress. While it soft launched in May of 2022, Schurman says they have several data sets that are awaiting clearing from the U.S. government, as well as the content analysis tool in development to launch possibly by the summer. Schurman also hopes they will curate the largest library of incident videos, images, and audio recordings.

The subject of UAP continues to attract new discussions from government officials and industry professions across aerospace, academia, and more. In Houston, Rice University's Woodson Research Center and its humanities department host one of the largest archives of UAP and paranormal data, notes, and research that include documents from CIA programs on remote viewing.

Schurman says he's looking to provide even more data and information in this space.

“This phenomenon, it’s implications to multiple aspects of our lives and possible security threats, all come down to a data problem and the organizations that have been in place to-date just have not had the level of cloud, data and AI engineering capabilities we take for granted and have access to in the private sector,” says Schurman. “My goal is to bring this all together, starting with PhenomAInon.”

Eric Ingram and Sergio Gallucci of SCOUT are focused on creating data-driven solutions to space technology management to save companies billions and prevent space debris. Photos courtesy of SCOUT

Tech startup lands in Houston to help space support services take off

space tech

A Virginia-based space company startup focusing on developing small and inexpensive satellites is making an out-of-this-world entrance in the Houston commercial innovation space.

SCOUT has been selected as part of the 2020 MassChallange's Texas in Houston cohort, a zero-equity startup accelerator, in the commercial space track and is planning a demonstration mission with the Johnson Space Center in 2021.

The startup, founded in 2019 by Eric Ingram and joined shortly after by Sergio Gallucci. Both have years of experience in innovative research and development, leading teams across academia, government, and industry. Their data will help manufacturers and operators extend satellite lifetimes, avoid failing satellites, reducing up to a billion dollars in losses.

"If we want further operate in space and grow our space presence overall," Eric Ingram, CEO-and-founder tells InnovationMap. "We need to have a safe environment to expand that presence so any time you have unchecked failures and space debris is a problem. We want to help take some of the riskiness out of space operations by providing data that doesn't already exist."

SCOUT provides a wide array of new products based on data to produce small and inexpensive satellites to perform in-space inspections of large and expensive satellites. Their data and spaceflight autonomy software helps spacecraft detect, identify, and refine models for observed objects to gather information and enable autonomous operations.

The space startup's observation and comprehension capabilities creates data products for customers, such as Spacecraft Sensor Suites and Satellite Inspections. The former is a sensor suite under current development to enable a new way to monitor satellites in space while the latter consists of their small satellites that can enable on-demand and on-site inspections for space assets.

This, according to Ingram, is changing the paradigm of operational risk in space.

"If we are able to better understand how these satellites age over time and diagnose problems before they become catastrophic failures," says Ingram "We can prevent space debris from even happening. The more safety and responsibility in space, the better it is for everyone to increase their technology and investment in what is a very rapidly growing industry."

Lost satellites tend to happen often, resulting in about $300 million lost in hardware and around $40 million annual revenue gone. Spacecrafts in outer space can be part of many unpredictable interactions that can be difficult to trace including solar activity, thermal, mechanical wear, and outgassing.

SCOUT will focus the rest of the year in growing their company, despite the setbacks caused by the coronavirus. Their priority is to meet their fundraising and technical milestones while engaging in strategic partnerships with satellite industry players.

"The space industry is growing and is becoming a more realistic and viable avenue for business growth and investment," says Ingram. "Houston is a diverse city with innovation at every front and the effort that NASA is going through to aid the commercial space industry, combined with the startup accelerators that there is a lot of adjacent opportunities and overlap in capabilities."

The NASA-backed Translational Research Institute for Space Health is innovating the future of life in space. Libby Neder Photography

Houston-based organization tasked by NASA to take risks and innovate solutions in space health

HOUSTON INNOVATORS PODCAST EPISODE 14

For Dorit Donoviel, innovation means risk — and there's not a lot that's riskier than traveling to and living in outer space. As director of Houston-based TRISH — the Translational Research Institute for Space Health — Donoviel is tasked by NASA to take some risks in order to innovate.

"Everyone tosses the word 'innovation' around, but that means, to us, taking risks in science. Health care, in particular, is very risk averse, but the space industry is taking risks every single day when they put people in a rocket and hurl them into space," Donoviel says on this week's episode of the Houston Innovators Podcast. "If we're going to mars, for example, we are going to put people at risk.

"For us to take risks in order to reduce risk is a really amazing opportunity."

TRISH works hand in hand with NASA's Human Research Program to identify the program's biggest concerns, and then tap into professors, researchers, and scientists from Baylor College of Medicine, California Institute of Technology, the Massachusetts Institute for Technology, and other partners in order to innovate solutions.

Some of the issues TRISH is working to provide solutions for range from protecting from radiation exposure on the moon and mars to personal health care — astronauts have to be a doctor to themselves when they are on the space station.

"That's a totally new model for health care, so we have to solve all those problems and invest in them," Donoviel says.

In a lot of ways, TRISH connects the dots of modern space research, explains Donoviel. The organization taps into its researcher network, as well as into startups and companies with innovative technologies, in order to deliver the best space innovations to NASA.

Donoviel goes into more details on how TRISH interacts with entrepreneurs as well as what new technologies the organization has seen success with in the episode. Stream the podcast below, and subscribe wherever you get your podcasts.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.